Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 404 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting No phase listed Observational

Vaccine Responses in Cancer

NCT06605625
Conditions
Viral Vaccines
Interventions
Influenza vaccination, SARS-CoV-2 vaccine, Zoster Vaccine Recombinant
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

NCT06038617
Conditions
Fever After Vaccination, Fever, Seizures Fever
Interventions
mRNA COVID-19 Vaccine, Routine Childhood Vaccinations
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Months to 4 Years
Enrollment
347 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
5
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Conditions
Adverse Reaction to Vaccine, COVID19 Vaccine
Interventions
BNT162b2, mRNA-1273, AZD1222, CoronaVac, Sinopharm, Gam-COVID-Vac, JNJ-78436735, CVnCoV, NVX-CoV2373, BBV152
Biological
Lead sponsor
Masaryk University
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

A Study of the Effectiveness of Moderna COVID-19 Vaccine

NCT05933304
Conditions
SARS-CoV-2, COVID-19
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
6 Months and older
Enrollment
927,004 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pasadena, California
Conditions
Vaccine Hesitancy, Climate Change
Interventions
Social diffusion intervention
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Covid19, Vaccine Refusal, Vaccine Hesitancy
Interventions
COVID-19 Vaccine Education at the Point of COVID-19 Testing
Behavioral
Lead sponsor
Xavier University of Louisiana.
Other
Eligibility
18 Years to 99 Years
Enrollment
377 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Covid19
Interventions
Text-Messaging (TM), Patient Navigation (PN)
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
65,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
COVID-19
Interventions
CVXGA (CVXGA50), COMIRNATY®
Biological
Lead sponsor
CyanVac LLC
Industry
Eligibility
18 Years to 100 Years
Enrollment
432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
55
States / cities
Anniston, Alabama • Phoenix, Arizona • Chula Vista, California + 44 more
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2, BNT162b2.B.1.351
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
12 Years to 50 Years
Enrollment
1,574 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
17
States / cities
Oakland, California • Milford, Connecticut • Hialeah, Florida + 13 more
Conditions
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
Interventions
protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Active, not recruiting No phase listed Observational Accepts healthy volunteers

COVID-19 Vaccine Responses in PIDD Subjects

NCT05321407
Conditions
X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
6 Months and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
St. Petersburg, Florida • Chapel Hill, North Carolina • Durham, North Carolina
Conditions
Pregnancy
Interventions
Observational
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 1 more
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

NCT05216510
Conditions
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Interventions
TNX-2110, TNX-2120, TNX-2130, CANDIN, Diluent
Biological
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Berlin, New Jersey
Conditions
Multiple Sclerosis, Covid19
Interventions
Not listed
Lead sponsor
St. Barnabas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Livingston, New Jersey
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Messaging on Pragmatic Outcomes Within an Integrated Healthcare System

NCT07838038
Conditions
Covid-19 Vaccination
Interventions
Vaccine choice message, Vaccine choice + platform-framed message, Vaccine choice + HCP trust-framed message, Vaccine choice + reactogenicity-framed message
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
1,300,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pasadena, California
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection, Electronic Health Record Review, Survey Administration
Biological · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma, Multiple Myeloma
Interventions
Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG, Antibiotics, Anti-viral agents, Anti-fungal agent, Anti-emetics
Biological · Diagnostic Test · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
SARS CoV 2 Infection, SARS CoV 2 Vaccination
Interventions
Not listed
Lead sponsor
Boston University
Other
Eligibility
5 Years to 75 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
COVID-19, Vaccines
Interventions
Reminder that facilitates action, Consistency framing, Information provision about the uniqueness of the bivalent booster, Information provision about bivalent booster eligibility, Information provision about the severity of COVID-19 symptoms
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
177,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Pharm-Olam, LLC
Industry
Eligibility
12 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
6
States / cities
Boston, Massachusetts • Omaha, Nebraska • Syracuse, New York + 3 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI

NCT05869968
Conditions
Spinal Cord Injuries, Traumatic Spinal Cord Injury, Healthy Controls, Flu Vaccine, COVID-19 Vaccine
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 89 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Manhasset, New York
Conditions
COVID-19
Interventions
Full Intervention, Enhanced Usual Care
Behavioral · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
988 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • Seattle, Washington